Evidence map›Paper›PMID 20376365›Full record

ArticlePloS one2010

CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells.

Thomas D Southgate, Owen J McGinn, Fernanda V Castro, Andrzej J Rutkowski, Mariam Al-Muftah, Georgi Marinov, Graeme J Smethurst, David Shaw, Christopher M Ward, Crispin J Miller and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Expression of Oncofetal Antigen 5T4 in Murine Taste Papillae.Frontiers in cellular neuroscience · 2019
    Article
  12. Cancer stem cell mobilization and therapeutic targeting of the 5T4 oncofetal antigen.Therapeutic advances in vaccines and immunotherapy · 2019
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Article
  18. Review
  19. Article
  20. A Subtype of Olfactory Bulb Interneurons Is Required for Odor Detection and Discrimination Behaviors.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Thomas D SouthgateImmunology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Owen J McGinn
Fernanda V Castro
Andrzej J Rutkowski
Mariam Al-Muftah
Georgi Marinov
Graeme J Smethurst
David Shaw
Christopher M Ward
Crispin J Miller
Peter L Stern
Cancer Research UK Manchester Institute · GBUniversity of Manchester · GB

Funding

Cancer Research UK
6 · The paper itself

Abstract

5T4 oncofetal molecules are highly expressed during development and upregulated in cancer while showing only low levels in some adult tissues. Upregulation of 5T4 expression is a marker of loss of pluripotency in the early differentiation of embryonic stem (ES) cells and forms an integrated component of an epithelial-mesenchymal transition, a process important during embryonic development and metastatic spread of epithelial tumors. Investigation of the transcriptional changes in early ES differentiation showed upregulation of CXCL12 and down-regulation of a cell surface protease, CD26, which cleaves this chemokine. CXCL12 binds to the widely expressed CXCR4 and regulates key aspects of development, stem cell motility and tumour metastasis to tissues with high levels of CXCL12. We show that the 5T4 glycoprotein is required for optimal functional cell surface expression of the chemokine receptor CXCR4 and CXCL12 mediated chemotaxis in differentiating murine embryonic stem cells and embryo fibroblasts (MEF). Cell surface expression of 5T4 and CXCR4 molecules is co-localized in differentiating ES cells and MEF. By contrast, differentiating ES and MEF derived from 5T4 knockout (KO) mice show only intracellular CXCR4 expression but infection with adenovirus encoding mouse 5T4 restores CXCL12 chemotaxis and surface co-localization with 5T4 molecules. A series of chimeric constructs with interchanged domains of 5T4 and the glycoprotein CD44 were used to map the 5T4 sequences relevant for CXCR4 membrane expression and function in 5T4KO MEF. These data identified the 5T4 transmembrane domain as sufficient and necessary to enable CXCR4 cell surface expression and chemotaxis. Furthermore, some monoclonal antibodies against m5T4 can inhibit CXCL12 chemotaxis of differentiating ES cells and MEF which is not mediated by simple antigenic modulation. Collectively, these data support a molecular interaction of 5T4 and CXCR4 occurring at the cell surface which directly facilitates the biological response to CXCL12. The regulation of CXCR4 surface expression by 5T4 molecules is a novel means to control responses to the chemokine CXCL12 for example during embryogenesis but can also be selected to advantage the spread of a 5T4 positive tumor from its primary site.

Indexed as

ChemotaxisAnimalsAntigens, SurfaceCell DifferentiationChemokine CXCL12Embryonic Stem CellsFibroblastsGene Expression Regulation, DevelopmentalMembrane GlycoproteinsMiceNeoplastic Stem CellsReceptors, CXCR4Antigens, SurfaceChemokine CXCL12Membrane GlycoproteinsReceptors, CXCR4Tpbg protein, mouse

Identifiers

PMID20376365
PMCPMC2848608
OpenAlexW1976823472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.